PROJECT SUMMARYMinority populations have a significant increase in cancer-associated risk factors and increased incidence ofpreventable diseases including cancer compared to their non-minority counterparts. Prevention measures suchas lifestyle intervention and vaccination to prevent viral infections linked to human carcinogenesis havedemonstrated promising results in minority populations yet there is still much to learn surrounding an individualsrisk of cancer and new opportunities to intervene before cancer arises including new and exciting approachesin immunoprevention. However limitations in comprehensive approaches to assess immune responses andimmunomodulatory properties of putative cancer prevention agents have muted the implementation of theseagents in the prevention window. Novel approaches for determining the role of the immune system in cancerdevelopment and prevention in combination with a comprehensive evaluation of immunomodulatory propertiesof putative prevention agents are required for future progress in this arena. This complexity is enhanced byvariations in immune responses between individual patients or subpopulations which must also be considered.This begins with the successful recruitment and retention of a cohort of diverse individuals to participate in clinicalresearch trials of novel cancer prevention agents to conduct these analyses. The specific aims of this diversitysupplement are designed to address these specific issues: 1) Examine the feasibility of novel technologies toimprove assessing immunomodulatory effects of study agents and immune signatures associated withresponse 2) Explore new strategies to improve recruitment and retention of study participants especiallyminorities to participate in CP-CTNet prevention trials 3) Provide training opportunities to an underrepresentedearly-stage investigator Dr. Centuori in clinical and translational chemoprevention/immunoprevention research.Through these studies we expect to determine the feasibility of the novel approaches and apply them to futureUA CT-CTNet trials enhance the understanding of complex immune responses associated with cancerprevention and generate highly relevant data to define the immunomodulatory potential of putative study agents.Furthermore by imploring new recruitment and retention strategies specifically aimed at minority recruitment weexpect that these findings will be greatly applicable to minority populations. Through participation in the proposedresearch and training activities Dr. Centuori will gain fundamental expertise in the performance of successfulearly phase cancer prevention trials as well as develop expertise in minority recruitment and community outreachto help her achieve her ultimate career goal of continuing to perform impactful clinical research inchemoprevention/immunoprevention and biomarker development in a manner which best serves diversitypopulations and reduces cancer health disparities by providing precision prevention to all.